Search the Newsreel

Amneal Pharmaceuticals Director John Kiely Sells 50,000 Shares and Donates 10,000 Shares on August 13, 2026

John Kiely, a director at Amneal Pharmaceuticals (NASDAQ: AMRX), sold 50,000 shares of Class A Common Stock at an average price of $17.64 and donated 10,000 shares to a donor-advised fund on August 13, 2026. After these transactions, Kiely's direct ownership in the company …

CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains

CorMedix Therapeutics CRMD delivered second-quarter 2026 adjusted earnings of 29 cents per share, which increased 4% year over year from 28 cents reported in the year-ago quarter. The reported figure beat the Zacks Consensus Estimate of 26 cents. Consolidated revenues were $101.9 million, which …

AMN Healthcare Services (NYSE:AMN) Stock Price Expected to Rise, Citizens Jmp Analyst Says

AMN Healthcare (AMN) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 5:00 p.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Randle ReecePresident and Chief Executive Officer - Caroline GraceChief Financial and Operating Officer - Brian Scott TAKEAWAYS Revenue -- $673 million, representing …

What Amneal Pharmaceuticals (AMRX)'s Higher Guidance and Complex Generics Pivot Means For Shareholders

Amneal Pharmaceuticals (AMRX) director reports 168,573-share transaction and updated holdings

Amneal Pharmaceuticals director Kevin J. Buchi reported a derivative exercise/conversion transaction involving 168,573 shares of Class A Common Stock on August 11, 2026. The shares were sold at a weighted average price of $17.18, with individual trades ranging from $17.07 to $17.31. Following this …

Amneal Pharmaceuticals (AMRX) legal chief Daly sells 216,613 shares in August trades

Amneal Pharmaceuticals' EVP and Chief Legal Officer, Jason B. Daly, sold a total of 216,613 shares of Class A Common Stock in two separate transactions on August 11 and August 12, 2026. The sales were open-market transactions, not pursuant to a Rule 10b5-1 trading …

Morgan Stanley (AMN) discloses 2.08M-share beneficial stake in AMN Healthcare

Morgan Stanley has disclosed a 5.4% passive ownership stake in AMN Healthcare Services, Inc., amounting to 2,076,006 shares of common stock as of June 30, 2026. The filing, a Schedule 13G, indicates that Morgan Stanley has shared voting power over 2,075,030 shares and shared …

AMN Healthcare Services: Strong Secular Growth Propels Earnings (NYSE:AMN)

Sei Investments Co. Acquires 34,925 Shares of AMN Healthcare Services Inc $AMN

Sei Investments Co. significantly increased its stake in AMN Healthcare Services Inc. (NYSE:AMN) by 204.7% in the first quarter, purchasing an additional 34,925 shares. This move is part of a broader trend of institutional investors adjusting their positions in AMN Healthcare, with several firms …

5 Revealing Analyst Questions From AMN Healthcare Services’s Q2 Earnings Call

AMN Healthcare Services reported Q2 results that surpassed analyst expectations, driven by strong demand in its Nurse and Allied Solutions segment and effective execution. The article highlights five key analyst questions from the earnings call, covering topics like contingent labor trends, margin assumptions, bill …

AMN Signals Greater Appetite for Acquisitions

AMN Healthcare Services Inc. plans to increase its acquisition activity as both the staffing market and the company's financial health improve. The company recently spent $3 million on two acquisitions, Jaide Health and Essential Leadership Assessment, and executives believe they are now in a …

Amneal (AMRX): Tushar Patel discloses 61.3M-share, 17.6% ownership in 13D/A

Tushar Patel has filed an Amendment No. 6 to his Schedule 13D, disclosing beneficial ownership of 61,341,678 shares of Amneal Pharmaceuticals Class A common stock, representing 17.6% of the outstanding shares. This updated ownership stake reflects shares acquired through the recent Kashiv BioSciences acquisition, …

Amneal Pharmaceuticals (AMRX) ownership shifts with $375M Kashiv deal and new shares

Amneal Pharmaceuticals, Inc. has completed its acquisition of Kashiv BioSciences, LLC for $375 million in cash and 28,942,098 shares of Class A Common Stock. This transaction has resulted in Chintu Patel becoming the beneficial owner of 32,576,528 shares, representing 9.4% of Amneal's Class A …

Amneal Pharmaceuticals (AMRX) director reports 283,632-share grant tied to Kashiv deal

Amneal Pharmaceuticals director Gautam Patel reported an indirect acquisition of 283,632 Class A common shares on August 10, 2026. These shares were received by limited liability companies he manages as part of Amneal's acquisition of Kashiv BioSciences, LLC. Following this transaction, Patel directly holds …

Amneal Pharmaceuticals (AMRX) Co-CEO linked entities receive 6.38M shares in Kashiv deal

Amneal Pharmaceuticals' Co-CEO, Chirag K. Patel, through entities he manages, acquired 6,381,734 Class A common shares on August 10, 2026. This share issuance was part of Amneal's acquisition of Kashiv BioSciences, LLC. After the transaction, Patel holds 1,393,470 shares directly and 21,269,420 shares indirectly …

Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?

Amneal Pharmaceuticals AMRX completed its acquisition of Kashiv BioSciences on Monday, creating an integrated global biosimilars platform spanning research, development, manufacturing and commercialization. The deal broadens Amneal's biosimilar capabilities as it seeks more consistent launches. The investment case still depends on integration, regulatory execution …

Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?

Amneal Pharmaceuticals AMRX enters the second half of 2026 with higher guidance and a broader product pipeline. The company is expanding complex generics, biosimilars and specialty medicines while adjusted earnings and EBITDA improve. The trade-off is clear. Rytary has lost exclusivity, generic pricing remains …

AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?

Amneal Pharmaceuticals AMRX shares have gained 44.8% over the past 12 weeks, putting the durability of the advance in focus. The rally has coincided with better operating results and a higher 2026 outlook. The next leg will depend on whether earnings growth, new launches …

AMN Healthcare: AI Could Give Nurses Back 240–400 Hours a Year

AMN Healthcare released a white paper projecting persistent healthcare workforce strain through 2030, citing an aging population, rising chronic diseases, and rural access gaps. The report forecasts a physician shortage of up to 86,000 by 2036 and notes that AI-enabled automation could save nurses …

AMN Healthcare Report Projects Persistent Workforce Strain Across Nursing, Allied Health, Physicians and Advanced Practitioners Through 2030

A new white paper by AMN Healthcare projects persistent workforce strain in nursing, allied health, physicians, and advanced practitioners through 2030. The report highlights that an aging population, rising chronic disease prevalence, and rural access gaps will continue to exacerbate staffing shortages. It also …

AMN Healthcare Services (AMN) Is Up 7.0% After Q2 Return To Profitability And Stronger Staffing Demand – Has The Bull Case Changed?

AMN Healthcare Services reported a return to profitability in Q2 2026 with US$21.16 million in net income and strong revenue of US$673.24 million, driven by increased demand in travel nursing and allied health staffing. The company's Q3 revenue guidance of US$640–US$655 million reinforces this …

AMN Healthcare Services (NYSE:AMN) Stock Price Down 6.6% - Here's Why

AMN Healthcare Services (NYSE:AMN) saw its stock price drop 6.6% in light trading, closing at $34.1950, despite strong recent quarterly results where it beat EPS and revenue expectations. Analyst sentiment is mixed, with an overall "Hold" rating and a consensus price target of $30.86. …

Amneal (AMRX) Is a Great Choice for 'Trend' Investors, Here's Why

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. Often, …

BMO Capital Keeps Their Buy Rating on AMN Healthcare Services (AMN)

1 Healthcare Stock Worth Your Attention and 2 We Ignore

1 Healthcare Stock Worth Your Attention and 2 We Ignore From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 18.3% over …

Dimensional Fund Advisors LP Sells 44,529 Shares of AMN Healthcare Services Inc $AMN

Dimensional Fund Advisors LP has reduced its stake in AMN Healthcare Services Inc. by 5.7%, selling 44,529 shares and retaining 741,209 shares valued at approximately $13.6 million. This comes after AMN Healthcare reported a strong second quarter with adjusted EPS of $0.77 and revenue …

AMN Healthcare (AMN) Stock May Be 13% Below Fair Value As Q2 Earnings Beat

AMN Healthcare Services' stock has seen a significant rally in 2026, making its valuation mixed with some indicators showing undervaluation and others suggesting it's overvalued. A Discounted Cash Flow (DCF) analysis indicates the stock could be 12.9% undervalued, supported by strong Q2 2026 earnings, …

Renaissance Technologies LLC Acquires 260,237 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Assenagon Asset Management S.A. Has $42.33 Million Stock Position in Amneal Pharmaceuticals, Inc. $AMRX

AMN Healthcare Services (AMN) Rebounds On Earnings As Investors Ask If The Recovery Is Priced In

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. AMN Healthcare Services (AMN) drew fresh attention after reporting second quarter 2026 earnings, with positive net income and earnings per share from continuing operations, alongside …

AMN Healthcare Services (AMN) Earnings Rebound Keeps Valuation In Focus

AMN Healthcare Services (AMN) recently reported a rebound to profit in its Q2 2026 results, alongside increased sales and new revenue guidance. Despite strong year-to-date and one-year share price returns, the stock has seen short-term pressure. The article explores whether the recent earnings rebound …

AMN Healthcare Services (AMN) Stock Jump Masks One Off Profit Boost